Strain development
DIRECTED EVOLUTION
Directed evolution is an essential part of successful strain engineering. We fine tune key parameters of chemical and physical mutagen exposure for each strain, from common cell factories like E. coli and S. cerevisiae to physiologically most complex bioactive (secondary) metabolite producing organisms (e.g. actinomycetes, Myxobacteria). To assure fast progress and optimal use of resources, we constantly optimize high-throughput screening conditions, achieving a fine balance between robustness of cultivation in μL-mL volumes and correlation with industrial-scale conditions.
NEW TOOLS FOR NEW PRODUCTS
Based on our in-depth knowledge of microbial physiology and biosynthetic pathways, insight from key analytical data and “omics” analyses, we conceptualize a comprehensive metabolic engineering or synthetic biology strategy for each project. We complement standard cloning procedures with DNA synthesis, in vitro and in vivo recombineering, strain-specific genetic tools and ABClone, Acies Bio proprietary platform for cloning fragments of up to several 100 kb of DNA. We have proprietary host strains available for heterologous expression of polyketides, peptides and proteins.
novel antibacterial polyketide by Myxobacteriareduction of impurities in an antibiotichigh yield strain for a vitaminheterologous polyketide expressionindustrial protein productionindustrial API technology
rapid non-GMO strain improvement in 6 months
increase of yield from 20 mg/L to 500 mg/L
25 g of previously unavailable API delivered
GMO without residual antibiotic markers
80% reduction of key impurity
no loss of target compound yield
metabolic engineering
about 30 copies of gene operon amplified in the genome
yield increased from 0.1 g/L to over 25 g/L
60 kb gene cluster cloned
heterologous polyketide production achieved
proprietary heterologous high expression platform used
secretion mechanism used; 90% secreted
protein tagged to simplify DSP
start with a wt-strain
24 months
from 100 mg/L to 10 g/L